Intrexon Corporation Has Two Overlooked Opportunities In The Anti-Infective Space
Trevor Lowenthal - at Seeking Alpha - Mon Dec 29, 11:51AM CST
XON: 39.30 (+1.05), OGEN: 0.91 (+0.16)
Update: Oragenics Pursues Strategic Alternatives For Its OTC Probiotic Business
Trevor Lowenthal - at Seeking Alpha - Tue Dec 23, 7:13AM CST
OGEN: 0.91 (+0.16)
Oragenics, Inc. to Explore Strategic Alternatives for its OTC Probiotic Products Business
Business Wire - Mon Dec 22, 3:54PM CST
Florida-based biopharmaceutical company Oragenics, Inc. (NYSE:MKT - OGEN) has announced today that its board of directors has authorized the exploration of strategic alternatives with respect to the Company's over-the counter (OTC) probiotic business. These alternatives could include joint ventures, strategic partnerships or alliances, a sale of the OTC probiotic products business or other possible transactions.
XON: 39.30 (+1.05), OGEN: 0.91 (+0.16)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 11:46AM CST
CIMT: 8.83 (+0.03), CLRB: 2.45 (+0.28), MPX: 8.13 (+0.31), FATE: 5.00 (-0.07), TTPH: 35.18 (-0.73), PHMD: 1.68 (+0.04), BIND: 6.06 (+0.21), AXPW: 0.39 (-0.04), CANF: 3.85 (+0.05), SYN: 2.13 (+0.18), RNA: 18.65 (unch), CLIR: 7.26 (-0.08), VSCI: 0.47 (unch), OCRX: 6.27 (-0.16), GALE: 1.68 (+0.06), REI: 10.00 (+0.27), OGEN: 0.91 (+0.16), PTP: 76.57 (-0.13), FPRX: 24.63 (+0.63)
Update: Oragenics Q3 Earnings
Trevor Lowenthal - at Seeking Alpha - Wed Nov 05, 10:53AM CST
OGEN: 0.91 (+0.16)
Update: Oragenics's CEO Resigns
Trevor Lowenthal - at Seeking Alpha - Fri Oct 31, 11:57AM CDT
OGEN: 0.91 (+0.16)
Oragenics, Inc. Announces Change in Management and Board of Directors
Business Wire - Thu Oct 30, 6:49PM CDT
Florida-based biopharmaceutical company Oragenics, Inc. (NYSE MKT:OGEN) has announced that on October 30, 2014 , Dr. John Bonfiglio resigned as Chief Executive Officer, President and director of Oragenics, Inc. to pursue other opportunities.
OGEN: 0.91 (+0.16)
Oragenics, Inc. Selects Merriman Capital as Capital Markets Advisor
Thomson Reuters ONE - Thu Sep 18, 8:00AM CDT
SAN FRANCISCO - September 18, 2014 - Merriman Capital, Inc. ("Merriman"
OGEN: 0.91 (+0.16)
Oragenics Appoints Key Hires to Drive Lantibiotic Platform Growth and Expansion
Business Wire - Wed Sep 10, 6:45AM CDT
Oragenics, Inc. (NYSE: OGEN), a leader in the development of novel, effective antibiotics and oral care probiotics, today announced two new appointments to the Product Development team. Joining the company are Guojun (Shawn) Nie Ph.D., as Director of Process Development, and Mr. Joel Ngoje as Senior Process Scientist. Together, the two bring almost 40 years of pharmaceutical, protein and process development experience to the company. Encouraging progress from the development of Oragenics' novel Lantibiotic platform has necessitated the accelerated expansion of the R & D team to position the pipeline for clinical success.
XON: 39.30 (+1.05), OGEN: 0.91 (+0.16)